INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 142 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2020. The put-call ratio across all filers is 0.65 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $2,737 | -55.9% | 52,549 | -46.4% | 0.00% | -50.0% |
Q2 2023 | $6,206 | +42.8% | 98,010 | +22.1% | 0.01% | +33.3% |
Q1 2023 | $4,346 | -40.0% | 80,253 | -41.3% | 0.01% | -40.0% |
Q4 2022 | $7,240 | -99.9% | 136,815 | +9.2% | 0.01% | +25.0% |
Q3 2022 | $5,827,000 | -44.0% | 125,234 | -31.3% | 0.01% | -42.9% |
Q2 2022 | $10,401,000 | -2.4% | 182,211 | +4.7% | 0.01% | +27.3% |
Q1 2022 | $10,654,000 | +95.2% | 174,113 | +67.0% | 0.01% | +120.0% |
Q4 2021 | $5,457,000 | +40.2% | 104,268 | -0.1% | 0.01% | +25.0% |
Q3 2021 | $3,891,000 | +2.6% | 104,380 | +12.4% | 0.00% | 0.0% |
Q2 2021 | $3,791,000 | +41.8% | 92,859 | +17.9% | 0.00% | +33.3% |
Q1 2021 | $2,673,000 | +5.9% | 78,793 | -0.7% | 0.00% | 0.0% |
Q4 2020 | $2,524,000 | +34.0% | 79,380 | +8.1% | 0.00% | +50.0% |
Q3 2020 | $1,884,000 | +42.2% | 73,410 | +42.3% | 0.00% | 0.0% |
Q2 2020 | $1,325,000 | +109.3% | 51,600 | +25.2% | 0.00% | +100.0% |
Q1 2020 | $633,000 | -55.2% | 41,200 | 0.0% | 0.00% | -50.0% |
Q4 2019 | $1,414,000 | +331.1% | 41,200 | -6.2% | 0.00% | – |
Q3 2019 | $328,000 | -42.5% | 43,900 | 0.0% | 0.00% | -100.0% |
Q2 2019 | $570,000 | +6.5% | 43,900 | 0.0% | 0.00% | 0.0% |
Q1 2019 | $535,000 | +7.0% | 43,900 | 0.0% | 0.00% | 0.0% |
Q4 2018 | $500,000 | -55.0% | 43,900 | -14.3% | 0.00% | 0.0% |
Q3 2018 | $1,111,000 | +22.8% | 51,200 | 0.0% | 0.00% | 0.0% |
Q2 2018 | $905,000 | -5.9% | 51,200 | +12.0% | 0.00% | 0.0% |
Q1 2018 | $962,000 | +86.1% | 45,700 | +28.0% | 0.00% | 0.0% |
Q4 2017 | $517,000 | -8.2% | 35,700 | 0.0% | 0.00% | 0.0% |
Q3 2017 | $563,000 | +27.1% | 35,700 | 0.0% | 0.00% | 0.0% |
Q2 2017 | $443,000 | -23.6% | 35,700 | -0.0% | 0.00% | 0.0% |
Q1 2017 | $580,000 | +7.6% | 35,701 | +0.0% | 0.00% | 0.0% |
Q4 2016 | $539,000 | -7.7% | 35,700 | -6.9% | 0.00% | 0.0% |
Q3 2016 | $584,000 | -48.9% | 38,344 | +30.2% | 0.00% | -50.0% |
Q2 2016 | $1,143,000 | -6.9% | 29,451 | -33.3% | 0.00% | 0.0% |
Q1 2016 | $1,228,000 | -14.2% | 44,159 | +66.0% | 0.00% | 0.0% |
Q4 2015 | $1,431,000 | +71.8% | 26,600 | +27.9% | 0.00% | +100.0% |
Q3 2015 | $833,000 | +17.8% | 20,800 | -6.0% | 0.00% | 0.0% |
Q2 2015 | $707,000 | – | 22,133 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Sarissa Capital Management LP | 640,000 | $25,626,000 | 6.33% |
Redmile Group, LLC | 1,322,592 | $52,957,000 | 4.01% |
SENZAR ASSET MANAGEMENT, LLC | 556,224 | $22,271,209,000 | 3.24% |
RA Capital Management | 314,349 | $12,587,000 | 1.81% |
WALL STREET ASSOCIATES | 205,657 | $8,235,000 | 1.58% |
Parametrica Management Ltd | 5,400 | $216,000 | 1.36% |
Rhenman & Partners Asset Management AB | 165,000 | $6,607,000 | 1.05% |
EAM Investors, LLC | 95,168 | $3,811,000 | 0.60% |
Rock Springs Capital Management LP | 180,000 | $7,207,000 | 0.58% |
WASATCH ADVISORS LP | 1,085,973 | $43,482,000 | 0.58% |